Back to Search Start Over

Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France

Authors :
Pierre Clerson
Damien Bonnet
Virginie Gressin
Xavier Jaïs
Maurice Beghetti
M. Voisin
Jean-Marc Schleich
Alain Fraisse
Sylvie Di Filippo
François Godart
Pascale Maragnès
Claire Dauphin
Service de cardiologie Pédiatrique [Marseille]
Hôpital de la Timone [CHU - APHM] (TIMONE)
Service de cardiologie et maladies vasculaires
Université de Rennes 1 (UR1)
Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes]
Service de Cardiologie Pédiatrique
Hospices Civils de Lyon (HCL)-Hôpital Louis Pradel [CHU - HCL]
Hospices Civils de Lyon (HCL)
Pediatric Cardiology Unit
Hôpital Universitaire de Genève
Actelion Pharmaceuticals
Actelion Pharmaceuticals France
Orgamétrie biostatistiques
Service de cardiologie Pédiatrique [Lille]
Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Centre de Référence M3C Malformations Cardiaques Congénitales Complexes
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-PRES Sorbonne Paris Cité-CHU Necker - Enfants Malades [AP-HP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes]
CHU Pontchaillou [Rennes]
Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-PRES Sorbonne Paris Cité-CHU Necker - Enfants Malades [AP-HP]
Hôpital de la Timone [CHU - APHM] ( TIMONE )
Université de Rennes 1 ( UR1 )
Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes]
Hospices Civils de Lyon ( HCL ) -Hôpital Louis Pradel [CHU - HCL]
Hospices Civils de Lyon ( HCL )
Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille )
Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -PRES Sorbonne Paris Cité-CHU Necker - Enfants Malades [AP-HP]
Source :
Archives of cardiovascular diseases, Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2010, 103 (2), pp.66-74. ⟨10.1016/j.acvd.2009.12.001⟩, Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2010, 103 (2), pp.66-74. 〈10.1016/j.acvd.2009.12.001〉
Publication Year :
2010
Publisher :
HAL CCSD, 2010.

Abstract

International audience; BACKGROUND: Limited data are available describing paediatric pulmonary arterial hypertension. AIMS: To characterize the epidemiology, management and impact on quality of life and outcome of paediatric pulmonary arterial hypertension, excluding persistent pulmonary hypertension of the newborn and pulmonary arterial hypertension caused by congenital heart disease. METHODS: In this multicentre study, children with pulmonary arterial hypertension were included and followed prospectively for two years at 21 referral centres in France. WHO functional class, 6-minute walk distance and quality of life (CHQ-PF50 questionnaire) were evaluated. RESULTS: Fifty children were included with a mean age of 8.9 +/- 5.4 years from May 2005 until June 2006. The estimated prevalence for pulmonary arterial hypertension was 3.7 cases/million. Patients had idiopathic pulmonary arterial hypertension (60%), familial pulmonary arterial hypertension (10%), pulmonary arterial hypertension associated with, but not caused by, congenital heart disease (24%), pulmonary arterial hypertension associated with connective tissue disease (4%) or portal hypertension (2%). During follow-up, the combination of pulmonary arterial hypertension-specific therapies was increasingly prescribed (44% patients versus 22% at inclusion). Patients remained stable regarding clinical status, 6-minute walk distance and quality of life. Survival estimates after one and two years were 86% (95% CI 76, 96) and 82% (95% CI 71, 93), respectively. CONCLUSIONS: In children, idiopathic/familial pulmonary arterial hypertension accounts for the majority of cases. A specific pulmonary arterial hypertension group in conjunction with congenital heart disease can be identified that resembles patients with idiopathic pulmonary arterial hypertension. Combined pulmonary arterial hypertension-specific therapies may have contributed to disease stability and favourable survival.

Subjects

Subjects :
Male
MESH : Hypertension, Pulmonary
Heart disease
MESH : Prevalence
Epidemiology
MESH : Prospective Studies
Pulmonary arterial hypertension
MESH : Antihypertensive Agents
0302 clinical medicine
MESH : Child
Surveys and Questionnaires
MESH: Child
Prospective Studies
Child
MESH: Treatment Outcome
MESH : Hemodynamics
Congenital heart defect
MESH : Infant
General Medicine
MESH: Follow-Up Studies
MESH: Infant
3. Good health
Child, Preschool
épidémiologie
Cardiology and Cardiovascular Medicine
Artery
Heart Defects, Congenital
medicine.medical_specialty
MESH: Hemodynamics
Hypertension, Pulmonary
Disease-Free Survival
03 medical and health sciences
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
MESH : Adolescent
Humans
MESH : Heart Defects, Congenital
MESH: Kaplan-Meier Estimate
MESH: Prevalence
MESH: Adolescent
MESH: Humans
MESH: Hypertension, Pulmonary
MESH: Questionnaires
MESH : Humans
Qualité de vie
MESH: Child, Preschool
Infant
MESH : Follow-Up Studies
MESH: Heart Defects, Congenital
medicine.disease
030228 respiratory system
MESH: Disease-Free Survival
MESH : Genetic Predisposition to Disease
MESH: Educational Status
MESH: Exercise Test
MESH: Female
MESH : Educational Status
[ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Pediatrics
Time Factors
[ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/Pediatrics
Hemodynamics
Kaplan-Meier Estimate
MESH : Child, Preschool
030204 cardiovascular system & hematology
[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Risk Factors
MESH: Risk Factors
Prevalence
MESH : Female
[ SDV.IB ] Life Sciences [q-bio]/Bioengineering
Prospective cohort study
Respiratory disease
MESH: Genetic Predisposition to Disease
MESH : Questionnaires
Hypertension artérielle pulmonaire
[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
MESH : Risk Factors
Treatment Outcome
medicine.anatomical_structure
Paediatric
Cardiology
MESH : Disease-Free Survival
Educational Status
Portal hypertension
Female
[SDV.IB]Life Sciences [q-bio]/Bioengineering
France
MESH : Time Factors
Quality of life
Adolescent
MESH : Male
Pédiatrie
MESH : Treatment Outcome
MESH : Kaplan-Meier Estimate
Internal medicine
medicine
Genetic Predisposition to Disease
MESH : France
Cardiopathie congénitale
Antihypertensive Agents
MESH: Antihypertensive Agents
[SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics
business.industry
MESH: Time Factors
MESH: Quality of Life
MESH : Quality of Life
Pulmonary hypertension
MESH: Male
MESH: Prospective Studies
MESH: France
MESH : Exercise Test
Exercise Test
business
Follow-Up Studies

Details

Language :
English
ISSN :
18752136
Database :
OpenAIRE
Journal :
Archives of cardiovascular diseases, Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2010, 103 (2), pp.66-74. ⟨10.1016/j.acvd.2009.12.001⟩, Archives of cardiovascular diseases, Elsevier/French Society of Cardiology, 2010, 103 (2), pp.66-74. 〈10.1016/j.acvd.2009.12.001〉
Accession number :
edsair.doi.dedup.....612dcd3cebd800ae63a3facfe2367a2d